View Item 

Show simple item record

How do we treat life‐threatening anemia in a J ehovah's W itness patient?

dc.contributor.authorPosluszny, Joseph A.en_US
dc.contributor.authorNapolitano, Lena M.en_US
dc.date.accessioned2015-01-07T15:24:07Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2015-01-07T15:24:07Z
dc.date.issued2014-12en_US
dc.identifier.citationPosluszny, Joseph A.; Napolitano, Lena M. (2014). "How do we treat life‐threatening anemia in a J ehovah's W itness patient?." Transfusion (12): 3026-3034.en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109968
dc.publisherWiley Periodicals, Inc.en_US
dc.titleHow do we treat life‐threatening anemia in a J ehovah's W itness patient?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109968/1/trf12888.pdf
dc.identifier.doi10.1111/trf.12888en_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceFitzgerald MC, Chan JY, Ross AW, et al. A synthetic haemoglobin‐based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma. Med J Aust 2011; 194: 471 ‐ 473.en_US
dc.identifier.citedreferenceLundy JB, Lewis CJ, Cancio LC, et al. Experience with the use of Hemopure in the care of a massively burned adult. Int J Burns Trauma 2014; 4: 45 ‐ 48.en_US
dc.identifier.citedreferenceJordan SD, Alexander E. Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia. J Pharm Pract 2013; 26: 257 ‐ 260.en_US
dc.identifier.citedreferenceMackenzie CF, Moon‐Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin‐based oxygen carrier in 54 patients with life‐threatening anemia. Anesth Analg 2010; 110: 685 ‐ 693.en_US
dc.identifier.citedreferenceLippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis‐stimulating agents. Semin Thromb Hemost 2010; 36: 537 ‐ 549.en_US
dc.identifier.citedreferenceChavez‐MacGregor M, Zhao H, Fang S, et al. Complications associated with erythropoietin‐stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results‐Medicare study. Cancer 2011; 117: 3641 ‐ 3649.en_US
dc.identifier.citedreferenceUS Food and Drug Administration. Physician request for an individual patient IND under expanded access for non‐emergency or emergency use. 2013. [cited 2014 Sep 19]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm.en_US
dc.identifier.citedreferenceSun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392 ‐ 400.en_US
dc.identifier.citedreferenceGanz T, Nemeth E. The hepcidin‐ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011; 2011: 538 ‐ 542.en_US
dc.identifier.citedreferenceSihler KC, Raghavendran K, Westerman M, et al. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma 2010; 69: 831 ‐ 837.en_US
dc.identifier.citedreferenceAshby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95: 505 ‐ 508.en_US
dc.identifier.citedreferenceSchwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti‐hepcidin Spiegelmer NOX‐H94 on inflammation‐induced anemia in cynomolgus monkeys. Blood 2013; 121: 2311 ‐ 2315.en_US
dc.identifier.citedreferenceHohlbaum A, Gille H, Christian J, et al. Iron mobilization and pharmacodynamics marker measurements in non‐human primates following administration of PRS‐080, a novel and highly specific anti‐hepcidin therapeutic [abstract]. Am J Hematol 2013; 5: E41.en_US
dc.identifier.citedreferenceFung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013; 98: 1667 ‐ 1676.en_US
dc.identifier.citedreferenceBodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004; 18: 105 ‐ 116.en_US
dc.identifier.citedreferenceGannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med 2002; 30: 1893 ‐ 1895.en_US
dc.identifier.citedreferenceCarson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42: 812 ‐ 818.en_US
dc.identifier.citedreferenceShander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion. Transfusion 2014; 54: 2688 ‐ 2695.en_US
dc.identifier.citedreferencede Araújo Azi LM, Lopes FM, Garcia LV. Postoperative management of severe acute anemia in a Jehovah's Witness. Transfusion 2014; 54: 1153 ‐ 1157.en_US
dc.identifier.citedreferenceTobian AA, Ness PM, Noveck H, et al. Time course and etiology of death in patients with severe anemia. Transfusion 2009; 49: 1395 ‐ 1399.en_US
dc.identifier.citedreferenceBeliaev AM, Marshall RJ, Smith W, et al. Mortality risk stratification in severely anaemic Jehovah's Witness patients. Intern Med J 2012; 42: e1 ‐ 3.en_US
dc.identifier.citedreferenceBeliaev AM, Marshall RJ, Smith W, et al. Treatment monitoring and mortality risk adjustment in anaemic Jehovah's Witnesses. ANZ J Surg 2013; 83: 161 ‐ 164.en_US
dc.identifier.citedreferenceElliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573 ‐ 1584.en_US
dc.identifier.citedreferenceImamura R, Moriyama T, Isaka Y, et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor‐1alpha. Transplantation 2007; 83: 1371 ‐ 1379.en_US
dc.identifier.citedreferenceLundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol 2011; 589 ( Pt 6 ): 1265 ‐ 1271.en_US
dc.identifier.citedreferenceGoodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128 ‐ 133.en_US
dc.identifier.citedreferenceZarychanski R, Turgeon AF, McIntyre L, et al. Erythropoietin receptor agonists in critically ill patients. A meta‐analysis of randomized controlled trials. CMAJ 2007; 177: 725 ‐ 734.en_US
dc.identifier.citedreferenceCorwin HL, Gettinger A, Fabian TC, et al.; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965 ‐ 976.en_US
dc.identifier.citedreferenceElliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009; 16: 94 ‐ 100.en_US
dc.identifier.citedreferenceCharles A, Purtill M, Napolitano LM. Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. Anaesth Intensive Care 2006; 34: 793 ‐ 796.en_US
dc.identifier.citedreferenceArroliga AC, Guntupalli KK, Beaver JS, et al. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med 2009; 37: 1299 ‐ 1307.en_US
dc.identifier.citedreferenceNapolitano LM. Epoetin alfa in the critically ill: what dose? Which route? Crit Care Med 2009; 37: 1501 ‐ 1503.en_US
dc.identifier.citedreferenceVan Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773 ‐ 2778.en_US
dc.identifier.citedreferenceUrrechaga E, Borque L, Escanero JF. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. Biomed Res Int 2013; 2013: 603786.en_US
dc.identifier.citedreferenceBarsun A, Sen S, Palmieri TL, et al. Reducing postburn injury anemia in a Jehovah's Witness patient. J Burn Care Res 2014; 35: e258 ‐ 261.en_US
dc.identifier.citedreferenceLorentzen K, Kjær B, Jørgensen J. Supportive treatment of severe anaemia in a Jehovah's Witness with severe trauma. Blood Transfus 2013; 11: 452 ‐ 453.en_US
dc.identifier.citedreferenceVaziri K, Roland JC, Robinson LL, et al. Extreme anemia in an injured Jehovah's Witness: a test of our understanding of the physiology of severe anemia and the threshold for blood transfusion. J Trauma 2009; 67: E11 ‐ 13.en_US
dc.identifier.citedreferenceGafter‐Gvili A, Rozen‐Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy‐induced anaemia—systematic review and meta‐analysis of randomised controlled trials. Acta Oncol 2013; 52: 18 ‐ 29.en_US
dc.identifier.citedreferenceHarwin SF, Pivec R, Johnson AJ, et al. Revision total hip arthroplasty in Jehovah's Witnesses. Orthopedics 2012; 35: e1145 ‐ 1151.en_US
dc.identifier.citedreferenceSihler KC, Napolitano LM. Anemia of inflammation in critically ill patients. J Intensive Care Med 2008; 23: 295 ‐ 302.en_US
dc.identifier.citedreferenceClinicalTrials.gov. Expanded access study of HBOC‐201 (Hemopure) for the treatment of life‐threatening anemia. 2014. [cited 2014 May 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01881503.en_US
dc.identifier.citedreferenceClinicalTrials.gov. An assessment of the safety and pharmacokinetics of ascending doses of Sanguinate in healthy volunteers. NCT01847222; 2013. [cited 2014 May 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01847222.en_US
dc.identifier.citedreferenceJahr JS, Mackenzie C, Pearce LB, et al. HBOC‐201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008; 64: 1484 ‐ 1497.en_US
dc.identifier.citedreferenceNatanson C, Kern SJ, Lurie P, et al. Cell‐free hemoglobin‐based blood substitutes and risk of myocardial infarction and death: a meta‐analysis. JAMA 2008; 299: 2304 ‐ 2312.en_US
dc.identifier.citedreferenceFergusson DA, McIntyre L. The future of clinical trials evaluating blood substitutes. Editorial. JAMA 2008; 299: 2324 ‐ 2326.en_US
dc.identifier.citedreferenceRao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555 ‐ 1562.en_US
dc.identifier.citedreferenceGerber DR. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med 2008; 36: 1068 ‐ 1074.en_US
dc.identifier.citedreferenceHajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304: 1559 ‐ 1567.en_US
dc.identifier.citedreferenceWeiskopf RB. Hemoglobin‐based oxygen carriers: compassionate use and compassionate clinical trials. Anesth Analg 2010; 110: 659 ‐ 662.en_US
dc.identifier.citedreferenceDonahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin‐based oxygen carrier: a case report and review of literature. Transfusion 2010; 50: 1561 ‐ 1567.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trf12888.pdf
Size:
447.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.